Fig. 3From: Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United StatesCost-effectiveness plane (nivolumab vs. everolimus). ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-yearBack to article page